A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol

A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative agent of coronavirus disease 2019 (COVID-19), may lead to severe systemic inflammatory response, pulmonary damage, and even acute respiratory distress syndrome (ARDS). This in turn may result in...

Full description

Bibliographic Details
Main Authors: Sergio Fragoso-Saavedra, David A. Iruegas-Nunez, Alejandro Quintero-Villegas, H. Benjamín García-González, Isaac Nuñez, Sergio L. Carbajal-Morelos, Belem M. Audelo-Cruz, Sarahi Arias-Martínez, Yanink Caro-Vega, Juan José Calva, Verónica Luqueño-Martínez, Alejandra González-Duarte, Brenda Crabtree-Ramírez, José C. Crispín, Juan Sierra-Madero, Pablo F. Belaunzarán-Zamudio, Sergio I. Valdés-Ferrer
Format: Article
Language:English
Published: BMC 2020-10-01
Series:BMC Infectious Diseases
Subjects:
COVID-19
SARS-Cov-2
Mortality
Invasive mechanical ventilation
Immunomodulation
Pyridostigmine
Online Access:http://link.springer.com/article/10.1186/s12879-020-05485-7

Internet

http://link.springer.com/article/10.1186/s12879-020-05485-7

Similar Items